Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Trovagene Inc (NQ: TROV )

1.190 USD UNCHANGED
Last Price Updated: 6:26 PM EDT, May 7, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.190
Bid (Size) 1.160 (3)
Ask (Size) 1.260 (1)
Prev. Close 1.190
Today's Range 1.190 - 1.190
52wk Range N/A - N/A
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Trovagene Announces First Quarter 2020 Results and Highlights
Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal cancer,... 
From PR Newswire
Trovagene Announces Changing of Company Name to Cardiff Oncology and Appointment of Mark Erlander, PhD, as Chief Executive Officer
- New corporate name, Cardiff Oncology, reflects the Company's mission and commitment to turning the tide on cancer by developing new treatment options for cancer patients 
From PR Newswire

Performance

More News

Read More
Onvansertib Trial in KRAS-Mutated Colorectal Cancer Demonstrates Consistent Tumor Regression Across KRAS Mutation Subtypes and Durable Response
From PR Newswire
Trovagene Expands Board with Addition of Three Industry Leaders - James Armitage, MD, Lâle White, and Gary Pace, PhD
From PR Newswire
Trovagene to Present at the 19th Annual Needham Healthcare Conference
From PR Newswire
Trovagene Announces Acceptance of Phase 1b/2 KRAS-Mutated Metastatic Colorectal Cancer (mCRC) Trial Abstract for Presentation at the 2020 ASCO Annual Meeting
From PR Newswire
Trovagene Announces Three New Nominees for Election to Board of Directors
From PR Newswire
Trovagene Announces Fourth Quarter and Full-Year 2019 Results
From PR Newswire
Trovagene Presents Phase 2 Data Demonstrating the Ability of Onvansertib to Overcome Zytiga®-Resistance and Provide Clinical Benefit for mCRPC Patients
From PR Newswire
16 Healthcare Stocks Moving In Wednesday's Pre-Market Session
Tags BIOC TROV Pre/Market Outlook
From Benzinga
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
Tags ZFGN AXDX CMRX
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.